Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program
about
Changes in coping, pain, and activity after cognitive-behavioral training: a randomized clinical trial for pediatric sickle cell disease using smartphones.National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008.Systematic and Meta-Analytic Review: Medication Adherence Among Pediatric Patients With Sickle Cell Disease.Pediatric sickle cell disease: past successes and future challenges.Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia.Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.Distance from an Urban Sickle Cell Center and its Effects on Routine Healthcare Management and Rates of Hospitalization.HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters.From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea.Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings
P2860
Q27318600-7F8512B8-D1F6-43FB-A3F0-87A2641C775BQ34253814-9078C110-D4EA-4685-B0B9-97BF5BE484DDQ38589127-D0EC533E-2E15-48D3-98AE-D664CC0475D3Q38814652-EDEA1AAE-CDDA-4FEB-80D5-5807B67E99F9Q38957972-226176F6-2972-4CFD-B81A-37A60A891542Q39143787-5703EBDF-3C0C-492C-BEB3-B701FFF254C3Q39268375-732B40AB-7D47-4853-A807-3A3A9DE7E463Q40313693-521C39FC-DB42-41A1-BB29-15EFF07839C0Q52639727-19C0CBE0-9726-4F63-B5CF-42D364EF95AEQ54735877-1DD6726F-F5DE-4B38-A453-A7637CA94365Q55301501-B7431914-ABC0-4F46-A9C7-76B133D7AD83Q55513319-B9B14284-1675-4802-85DA-12308DAE55E8Q58765141-9EC7AD7A-2F29-418B-9140-DAEF3731DECE
P2860
Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Hydroxyurea use and hospitaliz ...... pediatric sickle cell program
@ast
Hydroxyurea use and hospitaliz ...... pediatric sickle cell program
@en
Hydroxyurea use and hospitaliz ...... pediatric sickle cell program
@nl
type
label
Hydroxyurea use and hospitaliz ...... pediatric sickle cell program
@ast
Hydroxyurea use and hospitaliz ...... pediatric sickle cell program
@en
Hydroxyurea use and hospitaliz ...... pediatric sickle cell program
@nl
prefLabel
Hydroxyurea use and hospitaliz ...... pediatric sickle cell program
@ast
Hydroxyurea use and hospitaliz ...... pediatric sickle cell program
@en
Hydroxyurea use and hospitaliz ...... pediatric sickle cell program
@nl
P2093
P2860
P1433
P1476
Hydroxyurea use and hospitaliz ...... pediatric sickle cell program
@en
P2093
Banu Aygun
Fawaz Mzayek
James G Gurney
Jane S Hankins
Kerri A Nottage
Matthew Smeltzer
Winfred C Wang
P2860
P304
P356
10.1371/JOURNAL.PONE.0072077
P407
P577
2013-08-14T00:00:00Z